Cancer care has changed. The way we diagnose, test, match treatments, and pursue clinical trials is moving rapidly into the age of precision medicine. Yet in many hospitals and surgery centers, the way biopsy tissue is handled has not fully caught up.
For decades, the default process has been to preserve biopsy tissue using formalin-fixed paraffin embedding, commonly known as FFPE. FFPE is useful for traditional pathology and diagnosis, but it was never designed for the full range of advanced cancer testing now available. Today, cancer care may involve genomic profiling, biomarker testing, immunotherapy analysis, treatment effectiveness testing, personalized vaccine development, organoid creation, and clinical trial matching. Many of these options depend on having high-quality tumor tissue available.
That is why cryopreservation deserves a serious place in the modern cancer conversation.
Precision medicine has raised the standard. Tissue management must rise with it.
Precision medicine is built on one simple idea: your cancer is not exactly like anyone else’s cancer. The more your care team can learn about the biology of your tumor, the more intelligently they can evaluate treatment options.
The National Cancer Institute explains that biomarker testing looks for genes, proteins, and other tumor markers that can provide information about a person’s cancer and may help doctors choose treatment. NCI’s precision medicine trials have also used genomic testing to match patients with therapies based on specific genetic changes in their tumors.
That is the direction cancer care is moving: more testing, more personalization, more treatment matching, and more clinical trial opportunities.
But here is the part patients are not always told clearly enough:
Advanced testing often depends on the quality, quantity, and preservation method of the biopsy tissue.
Once your tissue is collected, the preservation decision can affect what may be possible later. If all available tissue is processed only for traditional diagnostics, the patient may lose the opportunity to use that same tissue for future advanced testing, clinical trial screening, or personalized therapy development.
Cryopreserved tissue helps preserve options.
Cryopreservation means tissue is frozen and stored in a way designed to better protect biological integrity over time. For patients, that matters because cancer treatment is not always a straight line.
A patient may need first-line treatment. Then second-line treatment. Then clinical trial matching. Then genomic re-analysis. Then immunotherapy evaluation. In some cases, a patient may later become eligible for treatment effectiveness testing or personalized vaccine research.
If no high-quality tissue remains, those options may become harder, delayed, or unavailable.
Think of cryopreserved tissue as a biological backup plan. It does not guarantee a specific treatment. It does not replace your doctor’s judgment. But it helps preserve the possibility of asking better questions later:
Can this tumor be tested against multiple therapies before they are tried in the patient?
Are there biomarkers that suggest a targeted therapy or immunotherapy option?
Could this tissue help qualify the patient for a clinical trial?
Could this sample support future testing that does not exist yet today?
That is the peace of mind cryopreservation offers.
If your doctor is not discussing cryopreservation, are you getting the whole story?
This is not about blaming doctors. Physicians are under pressure. Biopsy workflows are complex. Pathology requirements come first. Many hospitals still operate within legacy tissue-handling systems because that is how things have been done for decades.
But cancer care has changed.
Patients deserve to know that tissue preservation is not just a lab issue. It is a treatment-options issue.
If your doctor discusses the biopsy, the diagnosis, the risks, and the next step—but never discusses whether some tissue could be cryopreserved for advanced testing and future use—then an important part of the modern cancer care conversation may be missing.
The question patients should be asking is simple:
“Doctor, before my biopsy, can we discuss whether my tissue should be cryopreserved for advanced testing, treatment effectiveness testing, genomic analysis, immunotherapy evaluation, or future clinical trial matching?”
That one question could change what is possible later.
Insurance coverage is beginning to catch up.
The momentum behind precision medicine is not just scientific. It is also showing up in insurance policy.
As of the American Cancer Society Cancer Action Network’s March 2026 biomarker coverage update, 19 states had biomarker testing coverage laws for all state-regulated plans: Arizona, California, Connecticut, Georgia, Illinois, Indiana, Iowa, Kentucky, Maryland, Minnesota, Mississippi, Nebraska, New Mexico, New Jersey, New York, Oklahoma, Pennsylvania, Rhode Island, and Texas. Four additional states—Arkansas, Colorado, Florida, and Louisiana—had coverage for some plans.
That means more than 20 states now have some level of biomarker testing coverage protection, although coverage can vary by plan type, diagnosis, medical necessity, and whether the patient is in a state-regulated plan or a self-funded employer plan. Triage Cancer also notes that self-funded plans may not be subject to certain state insurance laws, which is an important distinction for patients checking benefits.
The direction is clear: policymakers increasingly recognize that biomarker and genomic testing are no longer “extra.” They are becoming core parts of modern cancer care.
But insurance coverage for testing does not solve the tissue problem by itself.
A test is only as useful as the sample available to run it.
Less than $1,000 can preserve options that may matter for years.
For cash-pay patients, cryopreservation may be far more accessible than many people assume. SpeciCare offers cancer tissue cryopreservation and storage options for less than $1,000 upfront, giving patients a practical way to protect access to high-quality tissue for future advanced testing and treatment planning.
Compared with the cost of cancer treatment, travel, missed work, medications, second opinions, or delayed therapy decisions, preserving tissue can be a small investment with potentially meaningful long-term value.
It is not about fear. It is about preparation.
Cancer patients often hear, “We’ll see what happens.” Cryopreservation gives patients and doctors something better: the ability to preserve more options before the door closes.
SpeciCare is leading the future of cancer tissue management.
SpeciCare exists because the cancer care system needs a better bridge between biopsy tissue, advanced testing, clinical trials, and long-term patient options.
SpeciCare’s cancer tissue management model is built around a modern reality: tissue is not medical waste. Tissue is information. Tissue is opportunity. Tissue is a resource that may help guide treatment today, open doors tomorrow, and support research that benefits patients in the future.
SpeciCare helps patients, clinicians, hospitals, researchers, and clinical trial partners think differently about biopsy tissue. Instead of treating tissue as something used once for diagnosis, SpeciCare supports a more forward-looking model:
Preserve it.
Protect it.
Test it when needed.
Match it to future opportunities.
Use it to advance precision medicine.
That is what cancer tissue management should look like in the precision medicine era.
The new standard should begin before the biopsy.
The most important time to talk about cryopreservation is before tissue is collected. Once the biopsy is complete and the tissue has already been processed, the opportunity to preserve fresh, high-quality material may be gone.
Patients should not have to learn about cryopreservation after it is too late.
Doctors should not have to wait until a patient’s first treatment fails before considering whether more advanced testing might be needed.
Hospitals and surgery centers should not treat precision medicine as an afterthought when the tissue required for precision medicine is collected at the very beginning.
The new standard in cancer care should include a tissue management conversation before biopsy.
Ask your doctor before your biopsy.
If you or someone you love is facing a biopsy, bronchoscopy, surgery, or suspected cancer diagnosis, ask these questions:
Can some of my biopsy tissue be cryopreserved?
Will there be enough tissue for advanced testing beyond diagnosis?
Could cryopreservation help preserve my eligibility for future genomic testing, treatment effectiveness testing, immunotherapy evaluation, personalized vaccine development, or clinical trials?
What happens to my tissue after diagnosis?
Who is helping me manage this tissue for future options?
If those questions are not being answered, you may not be getting the whole story.
Precision medicine has changed cancer care. Now tissue preservation must change with it.
Freeze cancer in its tracks. Ask your doctor about cryopreservation. Ask about advanced testing. Ask before your biopsy.
Recent Comments